SLGL - Sol-Gel Technologies Ltd.
| Previous close | 11.21 |
| Open | 11.38 |
| Bid | 10.00 x 900 |
| Ask | 18.00 x 1100 |
| Day's range | 10.51 - 11.90 |
| 52-week range | 6.11 - 21.00 |
| Volume | 139,236 |
| Avg. volume | 131,240 |
| Market cap | 206.914M |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.75 |
| Earnings date | 12 Aug 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.50 |
- Simply Wall St.
Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 40% Discount?
Does the September share price for Sol-Gel Technologies Ltd. (NASDAQ:SLGL) reflect what it's really worth? Today, we...
- Zacks
Sol-Gel Technologies Ltd. (SLGL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Investors Who Bought Sol-Gel Technologies (NASDAQ:SLGL) Shares A Year Ago Are Now Up 49%
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick...
- Zacks
Analysts Estimate Sol-Gel Technologies Ltd. (SLGL) to Report a Decline in Earnings: What to Look Out for
Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Supernus' ADHD Candidate Positive in 4th Phase III Study
Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.
